<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566759</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-831-1001</org_study_id>
    <secondary_id>2015-002295-24</secondary_id>
    <secondary_id>U1111-1168-6568</secondary_id>
    <secondary_id>15/SC/0412</secondary_id>
    <nct_id>NCT02566759</nct_id>
  </id_info>
  <brief_title>A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and pharmacokinetics (PK)
      of single and multiple rising doses of TAK-831 in healthy participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-831. TAK-831 is being tested to treat
      participant who have schizophrenia and cerebellar ataxia. This study will look at the PK,
      safety and tolerability of TAK-831 in healthy participants. The study will enroll
      approximately 120 participants. The study will include 4 parts: Part 1 (single-rising dose
      [SRD]), Part 2 (SRD/multiple-rising dose [MRD]), Part 3 (MRD) and Part 4 (relative
      bioavailability study). Participants will be randomly assigned (by chance, like flipping a
      coin) to receive either active drug TAK-831 or placebo which will remain undisclosed to the
      participant and study doctor during the study (unless there is an urgent medical need):

        -  Part 1, Cohort 1: single dose of TAK-831 100 mg

        -  Part 1, Cohort 2: single dose of TAK-831 250 mg

        -  Part 1, Cohort 3: single dose of TAK-831 500 mg

        -  Part 1, Cohort 4: single dose of TAK-831 30 mg

        -  Part 1, Cohort 5: single dose of TAK-831 750 mg

        -  Part 1, Cohort 6: single dose of TAK-831 10 mg

        -  Part 2, Cohort 1: single dose of TAK-831 30 mg

        -  Part 2, Cohort 2: single dose of TAK-831 100 mg

        -  Part 2, Cohort 3: single dose of TAK-831 200 mg

        -  Part 2, Cohort 4: single dose of TAK-831 400 mg

        -  Part 3, Cohort 1: TAK-831 400 mg

        -  Part 4: TAK-831 100 mg (Tablet Fasted + Tablet Fed + Suspension Fasted)

        -  Part 4: TAK-831 100 mg (Tablet Fed + Tablet Fasted + Suspension Fasted)

        -  Part 4: TAK-831 100 mg (Suspension Fasted+ Tablet Fed + Tablet Fasted)

      Dosing with TAK-831 will progress into study Part 2, 3 and 4, only after review of all
      available safety, tolerability, and PK data collected in Cohorts 1 to 6 of the Study Part 1.
      This single center trial will be conducted in the United Kingdom. The overall time to
      participate in this study is approximately up to 58 days. Participants will be admitted in
      the clinic for the up to 20 days, and will be contacted by telephone 14 days after last dose
      of study drug for a follow-up assessment.

      The study was terminated by Takeda due to the discomfort observed in the study participants
      from the CSF collection procedure in Part 3 of the study, hence it is was not feasible to
      collect further CSF samples that were required to meet the exploratory objectives of the
      study. Part 1, 2 and 4 of the study were completed as planned.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated by Takeda due to the discomfort observed in the study participants
    from the CSF collection procedure in Part 3 of the study.
  </why_stopped>
  <start_date>September 23, 2015</start_date>
  <completion_date type="Actual">July 12, 2016</completion_date>
  <primary_completion_date type="Actual">June 9, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
    <description>Clinical laboratory tests included hematology, serum chemistry and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
    <description>Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (&lt;) 85 millimeter of mercury (mm Hg) to greater than (&gt;) 180 mm Hg; diastolic blood pressure &lt; 50 mm Hg to &gt;110 mm Hg; pulse rate &lt;50 bpm to &gt;120 bpm; Temperature &lt;35.6 degree Celsius to &gt;37.7 degree Celsius.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
    <description>Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate &lt;50 beats per minute (bpm) to &gt;120 bpm; PR interval less than or equal to (&lt;=) 80 millisecond (msec) to greater than or equal to (&gt;=) 200 msec; QRS interval &lt;=80 msec to &gt;=180 msec; QT interval &lt;=300 msec to &gt;=460 msec; QTcB interval &lt;=300 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec; QT interval with Fridericia's correction method (QTcF) interval &lt;=50 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831</measure>
    <time_frame>Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831</measure>
    <time_frame>Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Schizophrenia, Cerebellar Ataxia</condition>
  <arm_group>
    <arm_group_label>Part 1, Cohort 1: TAK-831 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 milligram (mg), suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 2: TAK-831 250 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 250 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 3: TAK-831 500 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 500 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 4: TAK-831 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 5: TAK-831 750 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 750 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Cohort 6: TAK-831 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 10 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 1: TAK-831 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 30 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 2: TAK-831 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 3: TAK-831 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 200 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2, Cohort 4: TAK-831 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once on Day 1 and once daily from Days 4 to 16.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3, Cohort 1: TAK-831 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 400 mg, suspension, orally or TAK-831 placebo-matching suspension, orally, once daily from Days 1 to 14.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-831 100 mg, suspension, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 1, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once 30 minutes after starting a high fat meal on Day 1 of Period 2, followed by a washout interval of 5 days, further followed by TAK-831 100 mg, tablet, orally, once after an overnight fast of at least 10 hours on Day 1 of Period 3.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-831 Oral Suspension</intervention_name>
    <description>TAK-831 oral suspension.</description>
    <arm_group_label>Part 1, Cohort 1: TAK-831 100 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: TAK-831 250 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 3: TAK-831 500 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 4: TAK-831 30 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 5: TAK-831 750 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 6: TAK-831 10 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 1: TAK-831 30 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 2: TAK-831 100 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 3: TAK-831 200 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 4: TAK-831 400 mg</arm_group_label>
    <arm_group_label>Part 3, Cohort 1: TAK-831 400 mg</arm_group_label>
    <arm_group_label>Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)</arm_group_label>
    <arm_group_label>Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)</arm_group_label>
    <arm_group_label>Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-831 Placebo</intervention_name>
    <description>TAK-831 placebo-matching oral suspension.</description>
    <arm_group_label>Part 1, Cohort 1: TAK-831 100 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 2: TAK-831 250 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 3: TAK-831 500 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 4: TAK-831 30 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 5: TAK-831 750 mg</arm_group_label>
    <arm_group_label>Part 1, Cohort 6: TAK-831 10 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 1: TAK-831 30 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 2: TAK-831 100 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 3: TAK-831 200 mg</arm_group_label>
    <arm_group_label>Part 2, Cohort 4: TAK-831 400 mg</arm_group_label>
    <arm_group_label>Part 3, Cohort 1: TAK-831 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-831 Tablet</intervention_name>
    <description>TAK-831 tablet.</description>
    <arm_group_label>Part 4:TAK-831(Tablet Fasted+ Tablet Fed + Suspension Fasted)</arm_group_label>
    <arm_group_label>Part 4:TAK-831(Tablet Fed + Tablet Fasted + Suspension Fasted)</arm_group_label>
    <arm_group_label>Part 4:TAK-831(Suspension Fasted+ Tablet Fed + Tablet Fasted)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Should be capable of understanding and complying with protocol requirements.

          2. The participant or, when applicable, the participant's legally acceptable
             representative signs and dates a written, informed consent form and any required
             privacy authorization prior to the initiation of any study procedures.

          3. Healthy male or female aged between 18 to 55 years- Weighing at least 45 kilogram (kg)
             and has a body mass index (BMI) from 18.0 to 30.0 kilogram per square meter (kg/m^2).

          4. Male participant who is nonsterilized and sexually active with a female partner of
             childbearing potential agrees to use adequate contraception from signing of informed
             consent throughout the duration of the study and for 12 weeks after last dose.

          5. Female participant with no childbearing potential, defined as a participant that has
             been surgically sterilized (hysterectomy, bilateral oophorectomy or tubal ligation) or
             who is post menopausal (defined as continuous amenorrhea of at least 2 years and
             follicle-stimulating hormone [FSH] greater than [&gt;] 40 international units per liter
             [IU/L]).

        Exclusion Criteria:

          1. Received any investigational compound within 3 months prior to randomization.

          2. Is an immediate family member, study site employee, or is in a dependent relationship
             with a study site employee who is involved in the conduct of this study (example,
             spouse, parent, child, sibling) or may consent under duress.

          3. Has uncontrolled, clinically significant neurological (including seizure disorders),
             cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urologic,
             immunologic, endocrine disease, or psychiatric disorder, or other abnormality.

          4. Has a known hypersensitivity to any component of the formulation of TAK-831.

          5. Female participant is of childbearing potential.

          6. Has a positive urine drug result for drugs of abuse (defined as any illicit drug use)
             at Screening or Check-in.

          7. History of drug abuse (defined as any illicit drug use) or a history of alcohol abuse
             within 1 year prior to the Screening visit or is unwilling to agree to abstain from
             alcohol and drugs throughout the study. One unit is equivalent to a half-pint of beer
             or 1 single measure of spirits or 1 small glass of wine.

          8. Has taken any excluded medication, supplements, or food products during the time
             periods listed in the excluded medications and dietary products.

          9. Female participant is pregnant or lactating or intending to become pregnant before,
             during, or within 1 month after participating in this study; or intending to donate
             ova during such time period.

         10. Male participant intending to donate sperm during the course of this study or for 12
             weeks after the last dose of study medication.

         11. Has evidence of current cardiovascular, central nervous system, hepatic, hematopoietic
             disease, renal dysfunction, metabolic or endocrine dysfunction, serious allergy,
             asthma, hypoxemia, hypertension, seizures, or allergic skin rash.

         12. Has a QT interval with Fridericia's correction method (QTcF) &gt;450 millisecond (msec)
             (males) or &gt;470 msec (females) or PR outside the range of 120 to 220 msec, confirmed
             with one repeat testing, at the screening visit or check-in (Day -2).

         13. Has current or recent (within 6 months) gastrointestinal disease that would be
             expected to influence the absorption of drugs (that is, a history of malabsorption,
             esophageal reflux, peptic ulcer disease, erosive esophagitis, frequent [more than once
             per week] occurrence of heartburn, or any surgical intervention.

         14. Has a history of cancer, except basal cell carcinoma which has been in remission for
             at least 5 years prior to Day 1.

         15. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, or human immunodeficiency virus (HIV) antibody/antigen at Screening.

         16. Has used nicotine-containing products (including but not limited to cigarettes, pipes,
             cigars, chewing tobacco, nicotine patch or nicotine gum) within 28 days prior to
             Check-in. Cotinine test is positive at Screening or Check-in.

         17. Has poor peripheral venous access.

         18. Has donated or lost 450 milliliter (mL) or more of his or her blood volume (including
             plasmapheresis), or had a transfusion of any blood product within 45 days prior to
             first dose of medication.

         19. Has a Screening or Check-in abnormal (clinically significant) electrocardiogram (ECG).
             Entry of any participant with an abnormal (not clinically significant) ECG must be
             approved, and documented by signature by the principal investigator or designee.

         20. Has a supine blood pressure outside the ranges of 90 to 140 millimeter of mercury (mm
             Hg) for systolic and 50 to 90 mm Hg for diastolic, confirmed on repeat testing within
             a maximum of 30 minutes, at the Screening Visit or Check-in.

         21. Has a resting heart rate outside the range 40 to 100 bpm confirmed on repeat testing
             within a maximum of 30 minutes, at the Screening Visit or Check-in.

         22. Has abnormal Screening or check-in laboratory values that suggest a clinically
             significant underlying disease or participant with the following lab abnormalities:
             Alanine transaminase (ALT) and/or aspartate aminotransferase (AST) &gt;1.5 the upper
             limits of normal.

         23. Has a risk of suicide according to the Investigator's clinical judgment (example, per
             The Columbia Suicide Severity Rating Scale [C-SSRS]), or has scored &quot;yes&quot; on item 4 or
             item 5 of the Suicidal Ideation section of the C-SSRS, if this ideation occurred in
             the past 6 months, or &quot;yes&quot; on any item of the Suicidal Behavior section, except for
             the &quot;Non-Suicidal Self-Injurious Behavior&quot;, if this behaviour occurred in the past 2
             years.

         24. Has received TAK-831 in a previous clinical study.

         25. Participant is vegan or vegetarian (Part 4 only - food effect).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <results_first_submitted>August 1, 2017</results_first_submitted>
  <results_first_submitted_qc>August 1, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 6, 2018</results_first_posted>
  <last_update_submitted>August 1, 2017</last_update_submitted>
  <last_update_submitted_qc>August 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Ataxia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in the United Kingdom from 23 September 2015 to 12 July 2016.</recruitment_details>
      <pre_assignment_details>Healthy participants were enrolled in 4 part study to receive TAK-831: single rising dose (SRD) in Part 1; SRD/multiple rising dose (MRD) in Part 2; MRD in Part 3; relative bioavailability(rBA) in 3-sequence crossover in Part 4. Part 3 was terminated due to discomfort observed in participants from the cerebrospinal fluid (CSF) collection procedure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part 1: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Part 1: TAK-831 10 mg</title>
          <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P3">
          <title>Part 1: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P4">
          <title>Part 1: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P5">
          <title>Part 1: TAK-831 250 mg</title>
          <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P6">
          <title>Part 1: TAK-831 500 mg</title>
          <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P7">
          <title>Part 1: TAK-831 750 mg</title>
          <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="P8">
          <title>Part 2: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="P9">
          <title>Part 2: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="P10">
          <title>Part 2: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="P11">
          <title>Part 2: TAK-831 200 mg</title>
          <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="P12">
          <title>Part 2: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="P13">
          <title>Part 3: Placebo</title>
          <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
        </group>
        <group group_id="P14">
          <title>Part 3: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
        </group>
        <group group_id="P15">
          <title>Part 4: TAK-831 (Tablet Fasted+Tablet Fed+Suspension Fasted)</title>
          <description>TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 2, followed by a 5-day washout period, further followed by TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
        <group group_id="P16">
          <title>Part 4: TAK-831 (Tablet Fed+Tablet Fasted+Suspension Fasted)</title>
          <description>TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by a 5-day washout period, further followed by TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
        <group group_id="P17">
          <title>Part 4: TAK-831 (Suspension Fasted+Tablet Fed+Tablet Fasted)</title>
          <description>TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 2, followed by a 5-day washout interval, further followed by TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>All Parts</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="8"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="6"/>
                <participants group_id="P11" count="6"/>
                <participants group_id="P12" count="6"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P2" count="5">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P3" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P4" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P5" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P6" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P7" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P8" count="8">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P9" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P10" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P11" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P12" count="6">Participants from Part 1 and 2 did not continue in the washout period of Part 4 (crossover part).</participants>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8">Only participants of Part 4 continued in next period.</participants>
                <participants group_id="P16" count="8">Only participants of Part 4 continued in next period.</participants>
                <participants group_id="P17" count="8">Only participants of Part 4 continued in next period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="5"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="3"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="2"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Crossover Period (Part 4:5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Treatment (Part 4: 1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Crossover Period (Part 4:5 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Crossover Treatment (Part 4: 1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="8"/>
                <participants group_id="P16" count="8"/>
                <participants group_id="P17" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
                <participants group_id="P17" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Part 1: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Part 1: TAK-831 10 mg</title>
          <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B3">
          <title>Part 1: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B4">
          <title>Part 1: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B5">
          <title>Part 1: TAK-831 250 mg</title>
          <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B6">
          <title>Part 1: TAK-831 500 mg</title>
          <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B7">
          <title>Part 1: TAK-831 750 mg</title>
          <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="B8">
          <title>Part 2: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="B9">
          <title>Part 2: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="B10">
          <title>Part 2: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="B11">
          <title>Part 2: TAK-831 200 mg</title>
          <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="B12">
          <title>Part 2: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="B13">
          <title>Part 3: Placebo</title>
          <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
        </group>
        <group group_id="B14">
          <title>Part 3: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
        </group>
        <group group_id="B15">
          <title>Part 4: TAK-831 (Tablet Fasted+Tablet Fed+Suspension Fasted)</title>
          <description>TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 2, followed by a 5-day washout period, further followed by TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
        <group group_id="B16">
          <title>Part 4: TAK-831 (Tablet Fed+Tablet Fasted+Suspension Fasted)</title>
          <description>TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 2, followed by a 5-day washout period, further followed by TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
        <group group_id="B17">
          <title>Part 4: TAK-831 (Suspension Fasted+Tablet Fed+Tablet Fasted)</title>
          <description>TAK-831 100 mg, suspension, orally, in fasted state, once on Day 1 of Period 1, followed by a 5-day washout period, further followed by TAK-831 100 mg, tablet, orally, in fed state, once on Day 1 of Period 2, followed by a 5-day washout interval, further followed by TAK-831 100 mg, tablet, orally, in fasted state, once on Day 1 of Period 3.</description>
        </group>
        <group group_id="B18">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="8"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="6"/>
            <count group_id="B12" value="6"/>
            <count group_id="B13" value="1"/>
            <count group_id="B14" value="5"/>
            <count group_id="B15" value="8"/>
            <count group_id="B16" value="8"/>
            <count group_id="B17" value="8"/>
            <count group_id="B18" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18 to 55 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="5"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="7"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="1"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="0"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="0"/>
                    <measurement group_id="B17" value="0"/>
                    <measurement group_id="B18" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="5"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="8"/>
                    <measurement group_id="B17" value="8"/>
                    <measurement group_id="B18" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking History</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="4"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="5"/>
                    <measurement group_id="B17" value="6"/>
                    <measurement group_id="B18" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="1"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="1"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="3"/>
                    <measurement group_id="B17" value="2"/>
                    <measurement group_id="B18" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never drunk</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="2"/>
                    <measurement group_id="B16" value="1"/>
                    <measurement group_id="B17" value="1"/>
                    <measurement group_id="B18" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="3"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="6"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="6"/>
                    <measurement group_id="B16" value="7"/>
                    <measurement group_id="B17" value="7"/>
                    <measurement group_id="B18" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Caffeine Consumption</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caffeine consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="4"/>
                    <measurement group_id="B12" value="4"/>
                    <measurement group_id="B13" value="1"/>
                    <measurement group_id="B14" value="3"/>
                    <measurement group_id="B15" value="8"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No caffeine consumption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="2"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="0"/>
                    <measurement group_id="B14" value="2"/>
                    <measurement group_id="B15" value="0"/>
                    <measurement group_id="B16" value="4"/>
                    <measurement group_id="B17" value="4"/>
                    <measurement group_id="B18" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
        <time_frame>Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)</time_frame>
        <population>The safety set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O12">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O13">
            <title>Part 3: Placebo</title>
            <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
          </group>
          <group group_id="O14">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
          <group group_id="O15">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O16">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O17">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)</title>
          <population>The safety set included all participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="1"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="23"/>
                <count group_id="O16" value="23"/>
                <count group_id="O17" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="50.0"/>
                    <measurement group_id="O7" value="66.7"/>
                    <measurement group_id="O8" value="75.0"/>
                    <measurement group_id="O9" value="83.3"/>
                    <measurement group_id="O10" value="100.0"/>
                    <measurement group_id="O11" value="33.3"/>
                    <measurement group_id="O12" value="83.3"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="100.0"/>
                    <measurement group_id="O15" value="21.7"/>
                    <measurement group_id="O16" value="13.0"/>
                    <measurement group_id="O17" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose</title>
        <description>Clinical laboratory tests included hematology, serum chemistry and urinalysis.</description>
        <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
        <population>The safety set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O12">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O13">
            <title>Part 3: Placebo</title>
            <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
          </group>
          <group group_id="O14">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
          <group group_id="O15">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O16">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O17">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose</title>
          <description>Clinical laboratory tests included hematology, serum chemistry and urinalysis.</description>
          <population>The safety set included all participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="1"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="23"/>
                <count group_id="O16" value="23"/>
                <count group_id="O17" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="33.3"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="0"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</title>
        <description>Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (&lt;) 85 millimeter of mercury (mm Hg) to greater than (&gt;) 180 mm Hg; diastolic blood pressure &lt; 50 mm Hg to &gt;110 mm Hg; pulse rate &lt;50 bpm to &gt;120 bpm; Temperature &lt;35.6 degree Celsius to &gt;37.7 degree Celsius.</description>
        <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
        <population>The safety set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O12">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O13">
            <title>Part 3: Placebo</title>
            <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
          </group>
          <group group_id="O14">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
          <group group_id="O15">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O16">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O17">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose</title>
          <description>Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (&lt;) 85 millimeter of mercury (mm Hg) to greater than (&gt;) 180 mm Hg; diastolic blood pressure &lt; 50 mm Hg to &gt;110 mm Hg; pulse rate &lt;50 bpm to &gt;120 bpm; Temperature &lt;35.6 degree Celsius to &gt;37.7 degree Celsius.</description>
          <population>The safety set included all participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="1"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="23"/>
                <count group_id="O16" value="23"/>
                <count group_id="O17" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; lower criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="87.5"/>
                    <measurement group_id="O9" value="66.7"/>
                    <measurement group_id="O10" value="83.3"/>
                    <measurement group_id="O11" value="33.3"/>
                    <measurement group_id="O12" value="83.3"/>
                    <measurement group_id="O13" value="100.0"/>
                    <measurement group_id="O14" value="60.0"/>
                    <measurement group_id="O15" value="13.0"/>
                    <measurement group_id="O16" value="17.4"/>
                    <measurement group_id="O17" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; greater criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="33.3"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="20.0"/>
                    <measurement group_id="O15" value="4.3"/>
                    <measurement group_id="O16" value="8.7"/>
                    <measurement group_id="O17" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
        <description>Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate &lt;50 beats per minute (bpm) to &gt;120 bpm; PR interval less than or equal to (&lt;=) 80 millisecond (msec) to greater than or equal to (&gt;=) 200 msec; QRS interval &lt;=80 msec to &gt;=180 msec; QT interval &lt;=300 msec to &gt;=460 msec; QTcB interval &lt;=300 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec; QT interval with Fridericia’s correction method (QTcF) interval &lt;=50 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec.</description>
        <time_frame>Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4</time_frame>
        <population>The safety set included all participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: Placebo Pooled</title>
            <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O12">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O13">
            <title>Part 3: Placebo</title>
            <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
          </group>
          <group group_id="O14">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
          <group group_id="O15">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O16">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O17">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
          <description>Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate &lt;50 beats per minute (bpm) to &gt;120 bpm; PR interval less than or equal to (&lt;=) 80 millisecond (msec) to greater than or equal to (&gt;=) 200 msec; QRS interval &lt;=80 msec to &gt;=180 msec; QT interval &lt;=300 msec to &gt;=460 msec; QTcB interval &lt;=300 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec; QT interval with Fridericia’s correction method (QTcF) interval &lt;=50 msec to &gt;=500 msec or &gt;=30 msec change from baseline and &gt;=450 msec.</description>
          <population>The safety set included all participants who received at least 1 dose of study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="6"/>
                <count group_id="O12" value="6"/>
                <count group_id="O13" value="1"/>
                <count group_id="O14" value="5"/>
                <count group_id="O15" value="23"/>
                <count group_id="O16" value="23"/>
                <count group_id="O17" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt; lower cut-off point criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="16.7"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="37.5"/>
                    <measurement group_id="O9" value="33.3"/>
                    <measurement group_id="O10" value="50.0"/>
                    <measurement group_id="O11" value="0"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="20.0"/>
                    <measurement group_id="O15" value="13.0"/>
                    <measurement group_id="O16" value="21.7"/>
                    <measurement group_id="O17" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt; upper cut-off point criteria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="33.3"/>
                    <measurement group_id="O7" value="16.7"/>
                    <measurement group_id="O8" value="25.0"/>
                    <measurement group_id="O9" value="50.0"/>
                    <measurement group_id="O10" value="16.7"/>
                    <measurement group_id="O11" value="16.7"/>
                    <measurement group_id="O12" value="16.7"/>
                    <measurement group_id="O13" value="0"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="8.7"/>
                    <measurement group_id="O16" value="13.0"/>
                    <measurement group_id="O17" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O12">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O13">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="23"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.7" spread="26.95"/>
                    <measurement group_id="O2" value="313.3" spread="121.97"/>
                    <measurement group_id="O3" value="567.7" spread="218.76"/>
                    <measurement group_id="O4" value="905.8" spread="329.53"/>
                    <measurement group_id="O5" value="1304.5" spread="402.89"/>
                    <measurement group_id="O6" value="2121.7" spread="554.92"/>
                    <measurement group_id="O7" value="167.1" spread="39.95"/>
                    <measurement group_id="O8" value="467.2" spread="84.36"/>
                    <measurement group_id="O9" value="1087.3" spread="398.76"/>
                    <measurement group_id="O10" value="1095.5" spread="236.86"/>
                    <measurement group_id="O11" value="216.0" spread="104.68"/>
                    <measurement group_id="O12" value="377.7" spread="175.90"/>
                    <measurement group_id="O13" value="594.1" spread="288.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) is equal to (=) a+b*ln (dose), where a and b are the intercept and slope of the line, respectively. Dose proportionality was declared when the 90 percent (%) confidence interval (CI) of the slope lies entirely within the critical region (0.9483, 1.0517) for the dose range of 10 mg to 750 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.6662</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5969</ci_lower_limit>
            <ci_upper_limit>0.7355</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) = a+b*ln (dose), where a and b were the intercept and slope of the line, respectively. Dose proportionality was declared when the 90% CI of the slope lies entirely within the critical region (0.9139, 1.0861) for the dose range of 30 mg to 400 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.7795</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6597</ci_lower_limit>
            <ci_upper_limit>0.8993</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed lease square (LS) Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Least Square (LS) Mean Ratio</param_type>
            <param_value>0.362</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3043</ci_lower_limit>
            <ci_upper_limit>0.4301</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed LS Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Ratio</param_type>
            <param_value>1.799</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.4625</ci_lower_limit>
            <ci_upper_limit>2.2116</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831</title>
        <time_frame>Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.5" spread="45.85"/>
                    <measurement group_id="O2" value="560.7" spread="214.90"/>
                    <measurement group_id="O3" value="897.7" spread="192.73"/>
                    <measurement group_id="O4" value="1269.5" spread="451.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 3: Placebo</title>
            <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
          </group>
          <group group_id="O12">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
          <group group_id="O13">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O14">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O15">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
                <count group_id="O13" value="23"/>
                <count group_id="O14" value="23"/>
                <count group_id="O15" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.250" lower_limit="0.23" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.260" lower_limit="0.25" upper_limit="0.33"/>
                    <measurement group_id="O3" value="0.435" lower_limit="0.23" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.275" lower_limit="0.23" upper_limit="2.02"/>
                    <measurement group_id="O5" value="0.725" lower_limit="0.20" upper_limit="1.00"/>
                    <measurement group_id="O6" value="0.760" lower_limit="0.25" upper_limit="2.02"/>
                    <measurement group_id="O7" value="0.500" lower_limit="0.47" upper_limit="0.68"/>
                    <measurement group_id="O8" value="0.500" lower_limit="0.17" upper_limit="2.00"/>
                    <measurement group_id="O9" value="0.375" lower_limit="0.17" upper_limit="1.02"/>
                    <measurement group_id="O10" value="0.500" lower_limit="0.15" upper_limit="1.00"/>
                    <measurement group_id="O13" value="0.930" lower_limit="0.25" upper_limit="4.00"/>
                    <measurement group_id="O14" value="3.980" lower_limit="0.95" upper_limit="4.05"/>
                    <measurement group_id="O15" value="0.250" lower_limit="0.17" upper_limit="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O2" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O3" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O4" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O5" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O6" value="NA">Tmax for Part 1 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O7" value="0.500" lower_limit="0.48" upper_limit="0.53"/>
                    <measurement group_id="O8" value="0.365" lower_limit="0.23" upper_limit="0.98"/>
                    <measurement group_id="O9" value="0.500" lower_limit="0.20" upper_limit="0.50"/>
                    <measurement group_id="O10" value="0.490" lower_limit="0.23" upper_limit="1.00"/>
                    <measurement group_id="O13" value="NA">Tmax for Part 4 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O14" value="NA">Tmax for Part 4 was not planned to analyzed on Day 16.</measurement>
                    <measurement group_id="O15" value="NA">Tmax for Part 4 was not planned to analyzed on Day 16.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O12">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O13">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
          <units>nanogram*hour per milliliter (ng*hr/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="23"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.0" spread="17.02"/>
                    <measurement group_id="O2" value="463.8" spread="80.13"/>
                    <measurement group_id="O3" value="1186.8" spread="256.67"/>
                    <measurement group_id="O4" value="1900.8" spread="293.72"/>
                    <measurement group_id="O5" value="4111.1" spread="1599.18"/>
                    <measurement group_id="O6" value="5374.0" spread="1651.36"/>
                    <measurement group_id="O7" value="296.3" spread="95.31"/>
                    <measurement group_id="O8" value="938.4" spread="180.29"/>
                    <measurement group_id="O9" value="2030.2" spread="265.73"/>
                    <measurement group_id="O10" value="2832.7" spread="819.36"/>
                    <measurement group_id="O11" value="598.6" spread="310.31"/>
                    <measurement group_id="O12" value="1397.7" spread="434.45"/>
                    <measurement group_id="O13" value="1083.6" spread="302.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) = a+b*ln (dose), where a and b are the intercept and slope of the line, respectively. Dose proportionality was declared when the 90 % CI of the slope lies entirely within the critical region (0.9483, 1.0517) for the dose range of 10 mg to 750 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.8720</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8145</ci_lower_limit>
            <ci_upper_limit>0.9296</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) = a+b*ln (dose), where a and b were the intercept and slope of the line, respectively. Dose proportionality was declared when the 90% CI of the slope lies entirely within the critical region (0.9139, 1.0861) for the dose range of 30 mg to 400 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.9135</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8062</ci_lower_limit>
            <ci_upper_limit>1.0209</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed LS Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Ratio</param_type>
            <param_value>0.500</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4324</ci_lower_limit>
            <ci_upper_limit>0.5777</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed LS Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Ratio</param_type>
            <param_value>2.563</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.1000</ci_lower_limit>
            <ci_upper_limit>3.1275</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 1: TAK-831 10 mg</title>
            <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part 1: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O3">
            <title>Part 1: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Part 1: TAK-831 250 mg</title>
            <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O5">
            <title>Part 1: TAK-831 500 mg</title>
            <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Part 1: TAK-831 750 mg</title>
            <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
          </group>
          <group group_id="O7">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O8">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O9">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O10">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O11">
            <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
            <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O12">
            <title>Part 4: TAK-831 100 mg Tablet Fed</title>
            <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
          <group group_id="O13">
            <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
            <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="23"/>
                <count group_id="O12" value="23"/>
                <count group_id="O13" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.7" spread="22.02"/>
                    <measurement group_id="O2" value="499.2" spread="92.57"/>
                    <measurement group_id="O3" value="1271.4" spread="253.26"/>
                    <measurement group_id="O4" value="1945.5" spread="294.36"/>
                    <measurement group_id="O5" value="4140.7" spread="1602.32"/>
                    <measurement group_id="O6" value="5512.0" spread="1721.84"/>
                    <measurement group_id="O7" value="342.9" spread="46.80"/>
                    <measurement group_id="O8" value="980.5" spread="204.04"/>
                    <measurement group_id="O9" value="2092.7" spread="273.06"/>
                    <measurement group_id="O10" value="2866.6" spread="822.22"/>
                    <measurement group_id="O11" value="653.7" spread="308.86"/>
                    <measurement group_id="O12" value="1428.8" spread="433.24"/>
                    <measurement group_id="O13" value="1115.3" spread="296.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) = a+b*ln (dose), where a and b are the intercept and slope of the line, respectively. Dose proportionality was declared when the 90 % CI of the slope lies entirely within the critical region (0.9483, 1.0517) for the dose range of 10 mg to 750 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Power model</method>
            <param_type>Slope</param_type>
            <param_value>0.8505</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7925</ci_lower_limit>
            <ci_upper_limit>0.9084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Dose proportionality was evaluated using the following power model: ln (PK Parameter) = a+b*ln (dose), where a and b were the intercept and slope of the line, respectively. Dose proportionality was declared when the 90% CI of the slope lies entirely within the critical region (0.9139, 1.0861) for the dose range of 30 mg to 400 mg.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Power model</method>
            <param_type>Slope</param_type>
            <param_value>0.8415</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7618</ci_lower_limit>
            <ci_upper_limit>0.9212</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O13</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed LS Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Ratio</param_type>
            <param_value>0.543</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4797</ci_lower_limit>
            <ci_upper_limit>0.6149</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
            </group_id_list>
            <groups_desc>The point estimate and CI were obtained by taking the antilog of the difference in the log transformed LS Means.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>LS Mean Ratio</param_type>
            <param_value>2.336</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.9592</ci_lower_limit>
            <ci_upper_limit>2.7854</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831</title>
        <time_frame>Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part 2: TAK-831 30 mg</title>
            <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O2">
            <title>Part 2: TAK-831 100 mg</title>
            <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O3">
            <title>Part 2: TAK-831 200 mg</title>
            <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O4">
            <title>Part 2: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
          </group>
          <group group_id="O5">
            <title>Part 3: TAK-831 400 mg</title>
            <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
          </group>
        </group_list>
        <measure>
          <title>Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831</title>
          <population>The PK set included all participants with at least 1 estimable PK parameter for TAK-831. Due to discomfort observed in participants from the CSF collection procedure, Part 3 of the study was terminated hence no participants were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319.8" spread="83.06"/>
                    <measurement group_id="O2" value="1211.0" spread="236.45"/>
                    <measurement group_id="O3" value="1973.0" spread="316.34"/>
                    <measurement group_id="O4" value="3452.6" spread="1249.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Treatment-emergent adverse events are adverse events that started after the first dose of study drug and no more than 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Part 1: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Part 1: TAK-831 10 mg</title>
          <description>TAK-831 10 milligram (mg), suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E3">
          <title>Part 1: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Part 1: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Part 1: TAK-831 250 mg</title>
          <description>TAK-831 250 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Part 1: TAK-831 500 mg</title>
          <description>TAK-831 500 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E7">
          <title>Part 1: TAK-831 750 mg</title>
          <description>TAK-831 750 mg, suspension, orally, once on Day 1.</description>
        </group>
        <group group_id="E8">
          <title>Part 2: Placebo Pooled</title>
          <description>TAK-831 placebo-matching suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="E9">
          <title>Part 2: TAK-831 30 mg</title>
          <description>TAK-831 30 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="E10">
          <title>Part 2: TAK-831 100 mg</title>
          <description>TAK-831 100 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="E11">
          <title>Part 2: TAK-831 200 mg</title>
          <description>TAK-831 200 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="E12">
          <title>Part 2: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once on Day 1 and Days 4-16.</description>
        </group>
        <group group_id="E13">
          <title>Part 3: Placebo</title>
          <description>TAK-831 placebo-matching suspension, orally, once daily on Days 1-14.</description>
        </group>
        <group group_id="E14">
          <title>Part 3: TAK-831 400 mg</title>
          <description>TAK-831 400 mg, suspension, orally, once daily from Days 1-14.</description>
        </group>
        <group group_id="E15">
          <title>Part 4: TAK-831 100 mg Tablet Fasted</title>
          <description>TAK-831 100 mg, tablet, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
        </group>
        <group group_id="E16">
          <title>Part 4: TAK-831 100 mg Tablet Fed</title>
          <description>TAK-831 100 mg, tablet, orally, once in fed state on Day 1 of either Period 1, 2 or 3.</description>
        </group>
        <group group_id="E17">
          <title>Part 4: TAK-831 100 mg Suspension Fasted</title>
          <description>TAK-831 100 mg, suspension, orally, once in fasted state on Day 1 of either Period 1, 2 or 3.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E14" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E16" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E17" subjects_affected="4" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="4" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Swollen tongue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Eructation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter site related reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nail injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E14" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Trismus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="5" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E10" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E13" events="2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E14" events="16" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="5" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="9" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E10" events="13" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="9" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E12" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E12" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E13" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E14" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E15" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E16" events="0" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E17" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

